Devices and methods for detecting human metapneumovirus
View Patent ↗The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples.
1. A composition comprising a solid support and one or more human metapneumovirus (hMPV)-specific monoclonal antibodies selected from the group consisting of an hMPV monoclonal antibody produced by C2C10, an hMPV monoclonal antibody produced by F4A1, and an hMPV monoclonal antibody produced by CB7F3.
2. The composition of claim 1 , wherein said solid support comprises a test strip.
3. The composition of claim 2 , wherein said test strip is attached to a dipstick.
4. The composition of claim 1 , wherein said solid support comprises a microtitre plate.
5. The composition of claim 4 , wherein said plate is filled with said one or more hMPV-specific monoclonal antibodies.
6. The composition of claim 1 , wherein said solid support comprises a cell based assay.
7. The composition of claim 6 , wherein said cell based assay comprises tMK cells.
8. The composition of claim 1 , wherein said solid support further comprises an elution electrophoresis system.
9. The composition of claim 8 , wherein said elution electrophoresis system comprises a porous material under the influence of an electrical field.
10. The composition of claim 9 , wherein said porous material is selected from at least one of the group consisting of dextran, cellulose, acrylamide, polymeric particles, and silica.
11. The composition of claim 3 , wherein said dipstick comprises at least one compound selected from the group consisting of radioactive tracers, enzymes, colloidal metals, and substrates.
12. The composition of claim 1 , wherein said solid support comprises a microfluidic device.
13. The composition of claim 12 , wherein said microfluidic device comprises a ferrofluid, wherein said antibodies are attached to said ferrofluid.
14. The composition of claim 12 , wherein said microfluidic device comprises at least one microchannel in fluidic communication with at least one microchamber.
15. The composition of claim 2 , wherein said test strip comprises a fluid flow.
16. The composition of claim 9 , wherein said porous material comprises a fluid flow.
17. The composition of claim 12 , wherein said microfluidic device comprises a fluid flow.
18. The composition of claim 2 , wherein said test strip comprises nitrocellulose.
19. The composition of claim 1 , wherein said one or more human metapneumovirus (hMPV)-specific monoclonal antibodies are fluorescently labeled.
20. The composition of claim 1 , wherein said solid support further comprises a secondary anti-mouse antibody.
21. The composition of claim 20 , wherein said secondary anti-mouse antibody is coupled with an enzyme/substrate complex.
22. The composition of claim 21 , wherein said enzyme/substrate complex is a peroxidase-labeled anti-mouse IgG antibody and a peroxidase substrate.
23. A method for detecting the presence of human metapneumovirus in a sample, comprising:
contacting said sample with a solid support and one or more human metapneumovirus (hMPV)-specific monoclonal antibodies selected from the group consisting of an hMPV monoclonal antibody produced by C2C10, an hMPV monoclonal antibody produced by F4A1, and an hMPV monoclonal antibody produced by CB7F3, wherein said sample is contacted with said solid support under conditions such that said one or more hMPV-specific monoclonal antibodies binds to said human metapneumovirus.
24. The method of claim 23 , wherein said solid support comprises a test strip.
25. The method of claim 24 , wherein said test strip is attached to a dipstick.
26. The method of claim 23 , wherein said solid support comprises a microtitre plate.
27. The method of claim 26 , wherein said microtitre plate is filled with said one or more hMPV-specific monoclonal antibodies.
28. The method of claim 23 , wherein said assay comprises a cell based assay.
29. The method of claim 28 , wherein said cell based assay comprises tMK cells.
30. The method of claim 23 , wherein said solid support further comprises an elution electrophoresis system.
31. The method of claim 30 , wherein said elution electrophoresis system comprises a porous material under the influence of an electrical field.
32. The method of claim 31 , wherein said porous material is selected from at least one of the group consisting of dextran, cellulose, acrylamide, polymeric particles, and silica.
33. The method of claim 25 , wherein said dipstick comprises at least one compound selected from the group consisting of radioactive tracers, enzymes, colloidal metals, and substrates.
34. The method of claim 23 , wherein said solid support comprises a microfluidic device.
35. The method of claim 34 , wherein said microfluidic device comprises a ferrofluid, wherein said antibodies are attached to said ferrofluid.
36. The method of claim 34 , wherein said microfluidic device comprises at least one microchannel in fluidic communication with at least one microchamber.
37. The method of claim 24 , wherein said test strip comprises a fluid flow.
38. The method of claim 31 , wherein said porous material comprises a fluid flow.
39. The method of claim 34 , wherein said microfluidic device comprises a fluid flow.
40. The method of claim 24 , wherein said test strip comprises nitrocellulose.
41. The method of claim 23 , wherein said one or more human metapneumovirus (hMPV)-specific monoclonal antibodies are fluorescently labeled.
42. The method of claim 23 , wherein said solid support further comprises a secondary anti-mouse antibody.
43. The method of claim 42 , wherein said secondary anti-mouse antibody is coupled with an enzyme/substrate complex.
44. The method of claim 43 , wherein said enzyme/substrate complex is a peroxidase-labeled anti-mouse IgG antibody and a peroxidase substrate.